Crisugabalin

Synonyms: HSK16149
Crisugabalin 是一种具有口服活性的电压门控钙通道 α2δ 亚基选择性配体,在大鼠中的靶标 IC50 为 3.96 nM,它可抑制 [3H]加巴喷丁与 α2δ 亚基的结合、减少钙内流、降低神经元兴奋性并减少痛觉传导,还能减轻大鼠的机械性异常性疼痛、神经病理性疼痛和炎症痛,减少 II 期疼痛行为,因此可用于慢性疼痛、神经性疼痛、糖尿病性神经病变、纤维肌痛、炎症性疼痛、糖尿病周围神经性疼痛及带状疱疹后神经痛的相关研究。
产品编号: MS-R23030 纯度: 99.88% CAS No.: 2209104-84-5 分子式: C12H19NO2 分子量: 209.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Crisugabalin 是一种具有口服活性的电压门控钙通道 α2δ 亚基选择性配体,在大鼠中的靶标 IC50 为 3.96 nM,它可抑制 [3H]加巴喷丁与 α2δ 亚基的结合、减少钙内流、降低神经元兴奋性并减少痛觉传导,还能减轻大鼠的机械性异常性疼痛、神经病理性疼痛和炎症痛,减少 II 期疼痛行为,因此可用于慢性疼痛、神经性疼痛、糖尿病性神经病变、纤维肌痛、炎症性疼痛、糖尿病周围神经性疼痛及带状疱疹后神经痛的相关研究。

生物实验数据

生物活性 Crisugabalin is an orally active selective ligand of the voltage-gated calcium channel α2δ subunit with a target IC50 of 3.96 nM in rats; it inhibits the binding of [3H]gabapentin to the α2δ subunit, reduces calcium influx, decreases neuronal excitability, and diminishes pain transmission, and it also alleviates mechanical allodynia, neuropathic pain, and inflammatory pain and reduces phase II pain behavior in rats, making it useful for research on chronic pain, neuropathic pain, diabetic neuropathy, fibromyalgia, inflammatory pain, diabetic peripheral neuropathic pain, and postherpetic neuralgia.
体外研究
(In Vitro)

Crisugabalin (25 °C 下作用 30 min) 可强效结合 Wistar 大鼠大脑皮层细胞膜中的 VGCC α2δ 亚基,其 IC50 为 3.96 nM。

体内研究
(In Vivo)

Crisugabalin (1-30 mg/kg;p.o.;单次给药) 可剂量依赖性地升高 CCI 诱导的神经病理性疼痛大鼠的机械痛阈值。
Crisugabalin (1-30 mg/kg;p.o.;单次给药) 可呈剂量依赖性地升高 Streptozotocin (MS-Q80520) 诱导的糖尿病神经病变大鼠的机械痛阈值。
Crisugabalin (p.o.;单次给药;30 mg/kg) 可抑制间歇性冷应激 (ICS) 诱导的纤维肌痛小鼠的机械性痛觉超敏。
Crisugabalin (10-30 mg/kg;p.o.;单次给药) 呈剂量依赖性减轻福尔马林诱导的Ⅱ相炎症痛行为。
Crisugabalin (100 mg/kg;p.o.;单次给药) 可诱导大鼠产生镇静作用。

Animal Model: Sprague-Dawley (male, 160-180 g, CCI-induced neuropathic pain)
Dosage: 1 mg/kg;3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose
Result: Increased 50% PWT to 3.24-fold that of vehicle controls at 2 hours post-dosing (30 mg/kg, P < 0.001), with effects peaking at 6 hours post-dosing.
Produced PWT values of 12.93 g and 13.66 g at 2 and 4 hours post-dosing, respectively (10 mg/kg), similar to the 30 mg/kg group (11.93 g, 13.55 g).
Had a lower PWT than the 30 mg/kg group at 6 hours post-dosing (10 mg/kg) but efficacy comparable to 30 mg/kg pregabalin.
Significantly increased 50% PWT to 7.33 g vs.
3.11 g in vehicle controls at 4 hours post-dosing (3 mg/kg).
Had a minimum effective dose (MED) of 10 mg/kg for increased AUC of 50% PWT vs.
time.
Animal Model: Sprague-Dawley (male, 160-180 g, STZ-induced diabetic neuropathy)
Dosage: 1 mg/kg;3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose
Result: Significantly increased 50% PWT at 2 hours post-dosing (30 mg/kg), with efficacy persisting up to 24 hours post-dosing.
Increased 50% PWT to 2.4-fold at 2 hours post-dosing (10 mg/kg), with significant increases at 4 hours (10.55 g vs.
4.35 g) and 6 hours (11.74 g vs.
4.24 g), and efficacy persisting up to 8 hours post-dosing.
Doubled PWT vs.
vehicle controls at 6 hours post-dosing (3 mg/kg).
Had a MED of 10 mg/kg for increased AUC of 50% PWT vs.
time, with efficacy at 10 mg/kg comparable to 30 mg/kg pregabalin.
Animal Model: C57BL/6 (male, 18-25 g, ICS-induced fibromyalgia)
Dosage: 30 mg/kg
Administration: p.o.; single dose
Result: Had a MED of 30 mg/kg for increased 50% PWT.
Induced a 2.6-fold increase in 50% PWT, with efficacy comparable to 30 mg/kg pregabalin.
Animal Model: ICR (male, 25-35 g, formalin-induced inflammatory pain)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose
Result: Decreased formalin-induced phase II nociceptive motion counts in a dose-dependent manner.
Produced a 1.6-fold and 2.2-fold decrease in phase II motion counts vs.
vehicle controls at 10 mg/kg and 30 mg/kg, respectively.
Had efficacy at 30 mg/kg comparable to 30 mg/kg pregabalin.
Had no significant effect on phase I motion counts at 30 mg/kg.
Animal Model: Sprague-Dawley (male, 160-180 g)
Dosage: 100 mg/kg
Administration: p.o.; single dose
Result: Produced a 3-fold decrease in total distance traveled vs.
vehicle controls.
Had a MED of 100 mg/kg for sedative effects, with efficacy comparable to 100 mg/kg pregabalin.
性状 固体
颜色 White to off-white

化学信息

分子量 209.28
分子式 C12H19NO2
CAS No. 2209104-84-5
别名 HSK16149

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (477.83 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.7783 mL23.8914 mL47.7829 mL119.4572 mL
5 mM0.9557 mL4.7783 mL9.5566 mL23.8914 mL
10 mM0.4778 mL2.3891 mL4.7783 mL11.9457 mL
15 mM0.3186 mL1.5928 mL3.1855 mL7.9638 mL
20 mM0.2389 mL1.1946 mL2.3891 mL5.9729 mL
25 mM0.1911 mL0.9557 mL1.9113 mL4.7783 mL
30 mM0.1593 mL0.7964 mL1.5928 mL3.9819 mL
40 mM0.1195 mL0.5973 mL1.1946 mL2.9864 mL
50 mM0.0956 mL0.4778 mL0.9557 mL2.3891 mL
60 mM0.0796 mL0.3982 mL0.7964 mL1.9910 mL
80 mM0.0597 mL0.2986 mL0.5973 mL1.4932 mL
100 mM0.0478 mL0.2389 mL0.4778 mL1.1946 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础